Accession Number:

ADA426064

Title:

The BESCT Lung Cancer Program (Biology, Education, Screening, Chemoprevention, and Treatment)

Descriptive Note:

Annual rept. 16 Feb 2003-15 Feb 2004

Corporate Author:

M D ANDERSON CANCER CENTER HOUSTON TX

Personal Author(s):

Report Date:

2004-03-01

Pagination or Media Count:

78.0

Abstract:

Our long-term objectives are to define the molecular processes contributing to lung cancer development and progression in order to recognize genetic and phenotypic changes early enough to be reversed with molecularly-targeted therapy and to develop innovative therapeutic approaches to lung cancer. Therefore, the specific goals of this program are to understand molecular alterations in lung cancer, develop lung cancer prevention strategies, and implement experimental molecular approaches to lung cancer. We report herein that enolase-alpha down-regulation is common in NSCLC and associated with a poor clinical outcome IL-10 expression is lost in a subset of NSCLC and such loss predicts a poor clinical outcome in patients with stage I NSCLC the combination of the COX-2 inhibitor Celecoxib and the retinoid 4HPR results in more effective growth inhibition than each agent alone lack of PTEN expression in NSCLC may be related to promoter methylation and is of prognostic importance in stage I NSCLC Farnesyl Transferase Inhibitors down-regulate phosphorylated RAF and AKT and induce the ubiquitination of AKT protein.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE